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BACKGROUND: Impaired heart rate variability (HRV) is associated with increased mortality in sinus rhythm. However, HRV has 
not been systematically assessed in patients with atrial fibrillation (AF). We hypothesized that parameters of HRV may be pre-
dictive of cardiovascular death in patients with AF.
METHODS AND RESULTS: From the multicenter prospective Swiss-AF (Swiss Atrial Fibrillation) Cohort Study, we enrolled 1922 
patients who were in sinus rhythm or AF. Resting ECG recordings of 5-minute duration were obtained at baseline. Standard 
parameters of HRV (HRV triangular index, SD of the normal-to-normal intervals, square root of the mean squared differences 
of successive normal-to-normal intervals and mean heart rate) were calculated. During follow-up, an end point committee 
adjudicated each cause of death. During a mean follow-up time of 2.6±1.0 years, 143 (7.4%) patients died; 92 deaths were 
attributable to cardiovascular reasons. In a Cox regression model including multiple covariates (age, sex, body mass index, 
smoking status, history of diabetes mellitus, history of hypertension, history of stroke/transient ischemic attack, history of 
myocardial infarction, antiarrhythmic drugs including β blockers, oral anticoagulation), a decreased HRV index ≤ median 
(14.29), but not other HRV parameters, was associated with an increase in the risk of cardiovascular death (hazard ratio, 1.7; 
95% CI, 1.1–2.6; P=0.01) and all-cause death (hazard ratio, 1.42; 95% CI, 1.02–1.98; P=0.04).
CONCLUSIONS: The HRV index measured in a single 5-minute ECG recording in a cohort of patients with AF is an independent 
predictor of cardiovascular mortality. HRV analysis in patients with AF might be a valuable tool for further risk stratification to 
guide patient management.
REGISTRATION: URL: https://www.clini caltr ials.gov; Unique identifier: NCT02105844.
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Atrial fibrillation (AF) is the most common arrhyth-mia with rising incidence and is associated with a high risk for stroke, congestive heart failure (CHF), and death compared with the general popula-tion.1–5 Therefore, risk stratification in patients with AF is of high clinical importance.
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There is a large body of evidence that important 
prognostic information regarding mortality risk can be 
derived from the functional status of the cardiac auto-
nomic nervous system.6–14 Noninvasive assessment of 
the cardiac autonomic status can be achieved by the 
analysis of heart rate variability (HRV). In sinus rhythm 
(SR), depressed HRV has been associated with poor 
prognosis, in particular after myocardial infarction 
(MI)6–10,15–18 and CHF.11–14,19 However, in patients with 
AF, there are very limited data on the association of 
HRV and death. Nevertheless, cardiac autonomic dys-
function has also been linked to AF because the atria 
have a strong autonomic innervation.20,21 Furthermore, 
the AV node is highly susceptible to input from the au-
tonomic nervous system.22–26 Temporal changes in 
autonomic regulation have been shown to precede the 
onset of AF.27,28 In addition, autonomic nerve activity 
plays an important role in the maintenance of AF, and 
modulating autonomic nerve function contributes to 
AF control.29–35
Based on these findings, we hypothesize that im-
paired HRV may be predictive of cardiovascular death 
and other adverse outcomes in patients with AF. The 
Swiss-AF (Swiss Atrial Fibrillation) Cohort Study offers 
the unique opportunity to study the association of HRV 
and mortality in a large, unselected but well-defined 
cohort of patients with AF.
METHODS
A provision of the consent forms, as approved by the 
local ethics committee (Ethikkommission Nordwest-
und Zentralschweiz), does not allow data to be made 
publicly available. Researchers may contact the au-
thors for the potential submission of research propos-
als for future analyses.
Patient Population
Patients of the ongoing prospective, multicenter ob-
servational Swiss-AF cohort study performed in 14 
sites across Switzerland were included in this study. 
Detailed information of the study design and size has 
been published previously.36 In the Swiss-AF cohort 
study, a history of previously documented AF was re-
quired for inclusion. The main exclusion criteria were 
the presence of exclusively short, reversible AF epi-
sodes (eg, in sepsis or postoperatively) and acute ill-
ness of any cause within the past 4 weeks.
Of the 2415 patients enrolled in the Swiss-AF study, 
we excluded 14 patients because of missing baseline 
ECGs and 38 patients because of low-quality ECGs 
(Figure  1). After analysis of the baseline rhythm, we 
excluded 360 patients (14.9%) with paced atrial and/
or ventricular rhythm, 34 with atrial flutter, 6 with 
atrial tachycardia, 5 with junctional rhythm, 1 with a 
constant switch between atrial bursts and SR, and 1 
with pleomorphic premature ventricular contractions. 
Furthermore, we excluded 34 patients because of any 
missing and/or incomplete follow-up information or be-
cause of withdrawal of informed consent. Thus, 1922 
(79.6%) patients remained in the present analysis. The 
Swiss-AF study has been approved by local ethics 
committees in the participating centers; each partici-
pant gave written informed consent.
Clinical Measures
Standardized case report forms were used to obtain 
information on personal characteristics, risk factors, 
comorbidities, conventional pharmacological and in-
terventional treatment, and other factors. At baseline, 
CLINICAL PERSPECTIVE
What Is New?
• Heart rate variability (HRV) can be assessed in 
routine ambulatory 5-minute ECG recordings in 
patients with AF.
• Out of various conventional HRV parameters, 
HRV triangular index is an independent predic-
tor of cardiovascular and all-cause mortality in a 
cohort of patients with AF.
• To date, this is the largest study assessing the 
prognostic implications of impaired HRV in pa-
tients with AF.
What Are the Clinical Implications?
• Prognostic information regarding mortality risk 
can be derived from the functional status of the 
cardiac autonomic nervous system in patients 
with AF.
• Impairment of HRV triangular index identifies 
high-risk patients with AF.
• Short-term HRV analysis is a simple diagnos-
tic tool that is widely available at low cost and 
allows noninvasive risk stratification in patients 
with AF.
Nonstandard Abbreviations and Acronyms
AF atrial fibrillation
CHF congestive heart failure
HR hazard ratio
HRV heart rate variability
HRVI heart rate variability triangular index
MI myocardial infarction
NN normal-to-normal
SR sinus rhythm
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body height and weight were measured to calculate 
body mass index.
Assessment of HRV Parameters
At enrollment, all patients underwent a high-resolu-
tion 16-lead resting ECG recording for at least 5 min-
utes (CS-200 Excellence and CS-200 Touch, Schiller 
AG, Baar, Switzerland). All ECG recordings were 
saved with a sampling frequency of 1  kHz (signal 
bandwidth 0.04–387 Hz) and a resolution of 1 µV/bit. 
The high sampling frequency (twice as high as stand-
ard ECG devices) allowed state-of-the art bio-signal 
processing analyses during SR and AF. All collected 
recordings were saved in a central ECG core labo-
ratory at the Cardiocentro in Lugano, Switzerland.36 
The following parameters of HRV were calculated ac-
cording to previously published methods and by use 
of customized and validated software37: heart rate 
variability triangular index (HRVI), SD of the normal-
to-normal (NN) intervals, square root of the mean 
squared differences of successive NN intervals, and 
mean heart rate. For calculation of the HRVI, all NN 
intervals were first divided according to their length in 
bins of ≈8 ms (precisely 7.8125 ms=1/128 seconds). 
Then the number of NN intervals in the modal bin (ie, 
the maximum of the density distribution) was sought. 
Finally, the HRVI was defined as the total number of 
NN intervals divided by the number of NN intervals in 
the modal bin (Figure 2).37
Outcome Measurements
Follow-up investigations were performed on a yearly 
basis for assessment of clinical events. Every visit was 
performed at the reference local study center. If pa-
tients could not attend an appointment (eg, because 
of their medical condition), each study center offered 
them either a home visit or a telephone interview. The 
primary end point of this analysis was cardiovascu-
lar death. Secondary end points were defined as fol-
lows: all-cause mortality, MI, ischemic stroke, bleeding 
(major and clinically relevant nonmajor bleeding), and 
hospitalization as a result of CHF. Details on the defini-
tion of secondary end points can be found in Data S1. 
Clinical events were adjudicated by 2 investigators. If 
there was a discrepancy between the 2 investigators 
(eg, regarding the cause of death), a third investigator 
reviewed the event.
Statistical Analysis
Baseline characteristics were categorized accord-
ing to the patient’s baseline rhythm (SR versus AF). 
Continuous variables are presented as mean±SD and 
were analyzed using the t test. Categorical variables 
Figure 1. Flow chart of patient selection from the Swiss Atrial Fibrillation (Swiss-AF) Cohort Study.
HRVI indicates heart rate variability triangular index.
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are expressed as counts (percentages) and were 
compared using the chi-square test. Correlations 
between variables were assessed by Spearman rank 
correlation. We investigated the association of HRV 
parameters with the primary and secondary end 
points using Cox proportional hazard models. We 
built a bivariable Cox regression model (adjusted for 
age) and a multivariable Cox regression model (addi-
tionally adjusted for sex, body mass index, smoking 
status, history of diabetes mellitus, history of hyper-
tension, history of stroke/transient ischemic attack, 
history of MI, antiarrhythmic drugs [class Ic and III] 
including β blockers and oral anticoagulants) to test 
each of the HRV parameters in turn. To examine the 
effect of each HRV parameter, we dichotomized it to 
low or high. Because of the lack of widely accepted 
cut-offs in AF cohorts,37–39 we used each parameter’s 
observed median as our cut-off. Mortality rates were 
estimated by the Kaplan–Meier method. Hazard ra-
tios (HRs) are presented with 95% CIs. Possible effect 
modifications (interactions) were tested by including 
interaction terms to the proportional hazard models. 
Statistical analyses were performed using SPSS IBM 
SPSS Statistics for Windows, Version 25 (IBM Corp., 
Armonk, NY) and SAS 9.4 (SAS Corporation, Cary, 
NC).
RESULTS
Of the 1922 patients included in the present analy-
sis, 1121 patients were in SR (58%) and 801 patients 
(42%) were in AF at the time of baseline ECG record-
ing (Table 1). Patients in AF were older (75±8 versus 
71±8  years), had a higher prevalence of hyperten-
sion (75% versus 65%), diabetes mellitus (21% ver-
sus 13%), prior history of CHF (33% versus 16%), MI 
(17% versus 12%), stroke or transient ischemic attack 
(25% versus 17%), were more often treated with vita-
min K antagonists (53% versus 26%), and received 
direct oral anticoagulants less often (41% versus 
61%). Pulmonary vein isolation and electrocardio-
version had been performed more often in patients 
in SR at baseline (34% versus 6% and 38% versus 
33%, respectively).
Measures of HRV showed important, even rather 
weak, correlations with clinical variables of the study 
cohort (Table  S1). In particular, all HRV parameters 
correlated with age and CHA2DS2-VASc score, but not 
with sex. HRVI also correlated with systolic and dia-
stolic blood pressure and with AF symptoms.
During a mean follow-up of 2.6±1.0 years, 143 pa-
tients (7.4%) died. The cause of death was cardiovas-
cular in 92 patients (cumulative incidence rate of 1.87 
per 100 patient-years). Compared with survivors, non-
survivors were older (77±8 versus 72±8  years); were 
less frequently women (20% versus 28%; had a higher 
prevalence of hypertension (78% versus 68%), diabe-
tes mellitus (36% versus 15%), prior CHF (48% versus 
21%), and MI (21% versus 14%); had a higher CHA2DS2-
VASc score (4.4±1.6 versus 3.3±1.7); received vitamin 
K antagonists (55% versus 36%) more often; and were 
less often treated with antiarrhythmic drugs (18% versus 
29%) and direct oral anticoagulants (32% versus 54%).
Using a Cox proportional hazard model and ad-
justing for age, the HRVI ≤ median, but not other HRV 
parameters, was associated with an increase in car-
diovascular mortality (hazard ratio [HR], 1.71; 95% CI; 
Figure 2. Calculation of heart rate variability triangular index (HRVI).
Left upper figure: Standard resting ECG recording. Left lower figure: Corresponding tachogram of the RR intervals. Right figure: 
Calculation of HRVI. First, all normal-to-normal (NN) intervals are divided according to their length in bins of 8 ms. Second, the number 
of NN intervals in the modal bin (ie, the maximum of the density distribution) is sought. Finally, the HRVI is defined as the total number 
of NN intervals divided by the number of NN intervals in the modal bin. X indicates the modal bin; and Y, the number of NN intervals 
in the modal bin.
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1.13–2.60; P=0.01; Figure 3). This association remained 
similar after additionally adjusting for sex, body mass 
index, smoking status, history of diabetes mellitus, 
history of hypertension, history of stroke or transient 
ischemic attack, history of MI, antiarrhythmic drugs, β 
blockers, oral anticoagulants (HR, 1.70; 95% CI, 1.12–
2.59; P=0.01; Table 2).
We also found all-cause mortality to be higher for 
patients with HRVI ≤ median when adjusting for age 
l (HR, 1.48; 95%CI, 1.06–2.01; P=0.02). The direction 
and strength of the association remained the same 
also, when adjusting for the other potential confound-
ers (HR, 1.42; 95% CI, 1.02–1.98; P=0.04). We found 
no strong evidence for HRVI or any other HRV mea-
sure to be associated with any of the secondary end 
points, such as MI, ischemic stroke, bleeding (major 
and clinically relevant nonmajor bleeding), and hospi-
talizations caused by CHF (Table 3).
Subgroup analyses are shown in Figure 4. Interaction 
tests provided no support for different associations of 
HRVI with cardiovascular mortality depending on the 
grouping variables, particularly not when stratified by 
Table 1. Characteristics of Patients Grouped by Baseline Rhythm
Characteristic All Patients (N=1922) Patients in SR (N=1121) Patients in AF (N=801)
Age, y 73±8 71±8 75±8
Female sex, N (%) 532 (28) 351 (31) 181 (23)
Body mass index 27.7±4.9 27.3±4.8 28.3±4.9
Systolic/diastolic blood pressure, mm Hg 135±19/78±12 136±18/77±11 133±18/79±13
History of hypertension, N (%) 1325 (69) 725 (65) 600 (75)
History of diabetes mellitus, N (%) 311 (16) 147 (13) 164 (21)
Active and former smokers, N (%) 1080 (56) 626 (56) 454 (57)
History of electrocardioversion, N (%) 692 (36) 429 (38) 263 (33)
History of PVI, N (%) 425 (22) 375 (34) 50 (6)
History of myocardial infarction, N (%) 271 (14) 135 (12) 136 (17)
History of clinical stroke or TIA, N. (%) 384 (20) 188 (17) 196 (25)
History of heart failure, N (%) 446 (23) 184 (16) 262 (33)
CHA2DS2-VASc score 3.4±1.7 3.0±1.7 3.8±1.7
Antiarrhythmic therapy (class Ic and III) 535 (28) 343 (31) 192 (24)
β blockers, N (%) 1294 (67) 724 (65) 570 (71)
Direct oral anticoagulants, N (%) 1012 (53) 682 (61) 330 (41)
Vitamin K antagonists, N (%) 714 (37) 289 (26) 425 (53)
Data are means±SD or counts (percentages). AF indicates atrial fibrillation; CHA2DS2-VASc, congestive heart failure, hypertension, age ≥75 years (2 points), 
diabetes mellitus, prior stroke or TIA or thromboembolism (2 points), vascular disease, age 65–74 years, female sex; PVI, pulmonary vein isolation; SR, sinus 
rhythm; and TIA, transient ischemic attack.
Figure 3. Prognostic impact of heart rate variability triangular index (HRVI) in the entire study cohort.
Kaplan–Meier curves of cardiovascular and all-cause mortality stratified by the median heart rate variability triangular index. Mortality 
probabilities were significantly different (P=0.005 and P=0.008, respectively). Pts indicates patients.
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baseline rhythm (AF versus SR, P for interaction=0.52, 
Figures S1 and S2).
DISCUSSION
To the best of our knowledge, this is the largest study 
to have comprehensively investigated the prognostic 
power of HRV measures in a cohort of patients with 
AF. The main findings of our study are: (1) HRVI is an 
independent predictor of cardiovascular mortality in 
patients with AF; (2) HRVI also predicts all-cause mor-
tality; and (3) HRVI correlates with various clinical pa-
rameters such as age, CHA2DS2-VASc score, and AF 
symptoms.
Heart Rate Variability Analysis in AF
The parameters of HRV are strong and independent 
predictors of mortality in patients with cardiovascular 
Table 2. Cox Proportional Hazard Models for Cardiovascular Mortality
Parameter
No. of 
Events
Incidence/100  
atient Years
Bivariable Model 
HR (95% CI) P Value
Multivariable Model 
HR (95% CI) P Value
HRVI
HRVI >median 37 0.75 Ref. Ref.
HRVI ≤ median 55 1.12 1.71 (1.13–2.60) 0.01 1.70 (1.12–2.59) 0.01
SDNN
SDNN >median 46 0.93 Ref. Ref.
SDNN ≤ median 46 0.93 1.09 (0.72–1.64) 0.68 1.11 (0.74–1.67) 0.62
RMSSD
RMSSD > median 50 1.02 Ref. Ref.
RMSSD ≤ median 41 0.83 1.03 (0.68–1.56) 0.88 1.05 (0.69–1.61) 0.81
MHR
MHR >median 61 1.24 Ref. Ref.
MHR ≤ median 31 0.63 0.67 (0.43–1.03) 0.07 0.67 (0.438–1.05) 0.08
Data are hazard ratios (HRs) (95% CIs). P values were based on Cox proportional hazard models. Bivariable model was adjusted for age. Multivariable model 
was additionally adjusted for sex; body mass index; smoking status; history of diabetes mellitus; history of hypertension; history of stroke/ transient ischemic 
attack; history of myocardial infarction; and antiarrhythmic drugs, including β blockers and oral anticoagulation medications. HRVI indicates heart rate variability 
triangular index; MHR, mean heart rate; Ref., reference; RMSSD, square root of the mean squared differences of successive normal-to-normal intervals; and 
SDNN, standard deviation of the normal-to-normal intervals.
Table 3. Associations of Heart Rate Variability Index With Secondary End Points
Outcome
No. of  
Events
Incidence/100  
Patient-Years
Bivariable Model 
HR (95% CI) P Value
Multivariable Model 
HR (95% CI) P Value
All-cause mortality
HRVI > median 63 1.28 Ref. Ref.
HRVI ≤ median 80 1.62 1.48 (1.06–2.06) 0.02 1.42 (1.02–1.98) 0.04
Myocardial infarction
HRVI > median 22 0.45 Ref. Ref.
HRVI ≤ median 19 0.39 1.00 (0.54–1.85) 0.10 0.88 (0.47–1.64) 0.68
Ischemic stroke
HRVI > median 21 0.43 Ref. Ref.
HRVI ≤ median 20 0.41 1.10 (0.60–2.04) 0.75 1.05 (0.56–1.94) 0.89
Any bleeding
HRVI > median 147 3.23 Ref. Ref.
HRVI ≤ median 118 2.59 0.93 (0.73–1.18) 0.53 0.91 (0.72–1.12) 0.47
Hospitalization for heart failure
HRVI > median 91 1.94 Ref. Ref.
HRVI ≤ median 86 1.83 1.08 (0.80–1.45) 0.62 1.02 (0.76–1.37) 0.90
Data are hazard ratios (HRs) (95% CIs). P-values were based on Cox proportional hazard models. Bivariable model was adjusted for age. Multivariable model 
was additionally adjusted for sex; body mass index; smoking status; history of diabetes mellitus; history of hypertension; history of stroke/ transient ischemic 
attack; history of myocardial infarction; and antiarrhythmic drugs, including β blockers and oral anticoagulation medications. HRVI indicates heart rate variability 
triangular index; and Ref., reference.
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diseases who are in SR6–19 as the sinus node is the 
“instantaneous writer” of cardiac autonomic function. 
However, in AF, sinus node activity is suppressed and 
can therefore not be used as a marker of HRV. Constant 
concealed activation of the AV node during AF results 
in irregularly irregular AV nodal conduction and hence 
to RR interval irregularity, which poses a challenge to 
HRV analysis. Only very few studies have investigated 
HRV analysis during AF. Five studies showed an as-
sociation between depressed HRV, respectively de-
pressed heart rate irregularity, and adverse outcome in 
patients with AF.40–44 Stein et al assessed conventional 
time-domain measures of HRVI in 21 patients with AF 
suffering from severe mitral regurgitation.41 Here, the 
reduction of the SD of the average NN interval calcu-
lated over 5 minutes was a significant predictor of the 
combined risk of mortality or requirement for mitral 
valve surgery in univariable analysis. Frey et al inves-
tigated HRV in 35 patients with AF suffering from CHF 
with reduced ejection fraction.40 In this study, the SD 
of the average NN interval was the only independent 
parameter associated with survival on multivariable 
analysis. Yamada et al showed that even adjustment 
for cardiovascular comorbidities, entropy measures 
(Shannon entropy and approximate entropy) were sig-
nificant predictors of cardiac death.42 Finally, in a post 
hoc analysis of 155 AF patients with CHF included in 
the MUSIC (Muerte Subita en Insufficiencia Cardiaca) 
study, reduced approximate entropy, but not traditional 
HRV parameters (SD of the NN intervals, square root 
of the mean squared differences of successive NN 
intervals, the percentage of RR interval differences of 
successive NN intervals >50 ms = pNN50) predicted 
all-cause and sudden death.43 In a post hoc analysis 
of 68 patients who had AF at inclusion in the MADIT-II 
(Multicenter Automatic Defibrillator Implantation Trial II) 
study, Plantonov et al showed that after adjustment for 
significant clinical covariates, pNN20 <87%, but nei-
ther SD of the NN intervals, square root of the mean 
squared differences of successive NN intervals, nor 
approximate entropy, independently predicted mortal-
ity. To date, our study is by far the largest study that has 
assessed HRV in a cohort of patients with AF (n=1922). 
We were able for the first time to demonstrate that 
HRVI independently predicts cardiovascular mortality 
in patients with AF.
HRVI is a simple geometrical measure of HRV that 
can be derived from standard ECG recordings and 
expresses overall HRV.17 Depressed HRVI reflects 
sympathovagal imbalance, but does not distinguish 
between particular changes in sympathetic and vagal 
activity.45,46 Of note, other measures of HRV were not 
associated with mortality when adjusted for clinical co-
variates. This may be a result of the method of HRVI 
calculation, which is known to be robust and highly 
reproducible.47 It overcomes the disadvantages of 
other HRV measures, as it is less affected by noise 
and artifacts.48 For the calculation of HRVI, no difficult 
and time-consuming manual editing of the RR interval 
series is necessary. In contrast, methods based on SD 
of NN intervals require artifact-clear recognition of the 
ECG.48
Figure 4. Estimated cardiovascular mortality hazard ratios of heart rate variability triangular index ≤ median (14.29) vs > 
median by different grouping variables.
The interaction tests whether the hazard ratio depends on the grouping variable; a small P-value supports that the effect of the heart 
rate variability triangular index differs between groups.
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In general, cut-offs of HRV parameters have not 
been clearly established.37–39 Therefore, the classifica-
tion of “abnormal” HRV remains difficult as it depends 
on the selection of patients, analysis methods, length 
of ECG recordings, and conditions in which HRV is as-
sessed. This is one major reason why HRV analysis still 
has limited clinical use. According to the Task Force 
of the European Society of Cardiology and the North 
American Society of Pacing Electrophysiology, albeit 
published more than 20 years ago,37 an HRVI <15 is 
considered to be severely depressed, which is close to 
the median HRVI that we used in our cohort (ie, 14.29).
HRV Index as a Predictor of Outcome
The prognostic value of HRVI when assessed during 
SR has been investigated in various studies. Whereas 
both HRVI and left ventricular ejection fraction have 
been shown to perform equally well in predicting all-
cause mortality in survivors of acute MI, HRVI was a 
better predictor of arrhythmic complications than left 
ventricular ejection fraction.9 Furthermore, combining 
the left ventricular ejection fraction with HRVI improved 
specificity in predicting all-cause mortality. In another 
cohort of post-MI patients, low HRVI was shown to 
strongly predict arrhythmic events.49 In patients with 
chronic CHF, a reduced HRVI was also found to be 
related to survival, independent of and of incremental 
value to left ventricular function.11 Finally, even in the 
setting of coronary artery disease on chronic hemodi-
alysis, a patient group with a high burden of comorbid-
ity, decreased HRVI was a significant and independent 
predictor of cardiac death.50 Therefore, though con-
sistent with previous observations that reductions 
in HRVI are associated with adverse outcome, our 
findings show for the first time that HRVI is also as-
sociated with adverse outcomes in patients with AF. 
With regard to the results of subgroup analyses, the 
prognostic power of HRVI was not affected by baseline 
rhythm (SR versus AF). In addition, although β blockers 
and antiarrhythmic drugs have been described to alter 
HRV,51,52 HRVI predicted cardiovascular mortality irre-
spective of the intake of β blockers or antiarrhythmics. 
Of note, the numerically highest risk of cardiovascu-
lar death was observed in patients who were in AF on 
baseline ECG and had an impaired HRVI.
Limitations
Several limitations have to be taken into account when 
interpreting our results. First, we assessed parameters 
of HRV in short-term ECG recordings over 5 minutes, 
whereas the majority of prior studies have assessed 
HRV during 24-hour Holter recordings.6–11,13,14,17–19,40–42 
However, our results indicate that HRV assessed from 
short-term recordings may be used for initial risk strati-
fication of patients with AF. Nevertheless, it may be that 
HRV measured over longer periods may provide more 
prognostic information in patients with AF. Therefore, 
validation of our findings in 24-hour or 7-day Holter re-
cordings is warranted. Second, the majority of patients 
were treated with drugs that may modify HRV. However, 
in subgroup analyses we observed no association of 
antiarrhythmics or β blockers with any HRV measure 
or prognosis. Third, this study is not able to establish 
causality of the potential mechanisms linking HRV and 
outcome in patients with AF. Therefore, the question 
whether decreased HRV is part of the pathophysio-
logic pathway leading to increased mortality in patients 
with AF or merely a marker of poor prognosis cannot 
be answered. Although the prognostic power of HRVI 
was independent of multiple clinical covariates, it can-
not be excluded that reduced HRVI identified patients 
with unknown confounders with an impact on survival. 
Finally, this is a secondary, exploratory analysis from 
the Swiss-AF cohort and not the primary outcome.
Clinical Implications and Conclusions
Patients with AF are at high risk of serious cardiovas-
cular events; therefore, establishing a new clinical tool 
for the identification of high-risk patients with AF is im-
portant. Our data indicate that HRVI measured in a sin-
gle routine ambulatory 5-minute ECG-recording in AF 
patients is an independent predictor of cardiovascular 
mortality. This study suggests that analysis of the vari-
ability of the ventricular response in AF may also have 
prognostic implications when measured during AF. 
However, because of known limitations of HRV analy-
sis during AF, where an increased background HRV 
is present, analysis of a RR interval time series in AF 
may have to be approached differently. Therefore, the 
development of new indices that focus on quantifying 
RR-interval irregularity instead of RR-interval variability 
might be promising for risk stratification in AF in the 
future.
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Christian Sticherling, Thomas Szucs, Gian Voellmin, Leon Zwimpfer. Principal Investigator: Stefan 
Osswald; Local Principal Investigator: Michael Kühne 
 
University Hospital Bern: Faculty: Drahomir Aujesky, Urs Fischer, Juerg Fuhrer, Laurent Roten, Simon 
Jung, Heinrich Mattle; Research fellows: Luise Adam, Carole Elodie Aubert, Martin Feller, Claudio 
Schneider, Axel Loewe, Elisavet Moutzouri; Study nurses: Tanja Flückiger, Cindy Groen, Damiana 
Rakovic, Rylana Wenger, Lukas Ehrsam, Alexandra Nuoffer, Nathalie Schwab. Local Principal 
Investigator: Nicolas Rodondi 
 
Stadtspital Triemli Zurich: Christopher Beynon, Roger Dillier, Michèle Deubelbeiss,  Franz Eberli, 
Christine Franzini, Isabel Juchli, Claudia Liedtke, Jacqueline Nadler, Thayze Obst, Noreen Tynan, 
Xiaoye Schneider, Katrin Studerus, Dominik Weishaupt. Local Principal Investigator: Andreas Müller 
 
Kantonspital Baden: Simone Fontana, Silke Kuest, Karin Scheuch, Denise Hischier, Nicole Bonetti, 
Alexandra Grau, Jonas Villinger, Eva Laube, Philipp Baumgartner, Mark Filipovic, Marcel Frick, Giulia 
Montrasio, Stefanie Leuenberger, Franziska Rutz. Local Principal Investigator: Jürg-Hans Beer 
 
Cardiocentro Lugano: Angelo Auricchio, Adriana Anesini, Cristina Camporini, Giulio Conte, Maria Luce 
Caputo, Francois Regoli. Local Principal Investigator: Tiziano Moccetti  
 
Kantonsspital St. Gallen: Roman Brenner, David Altmann, Michaela Gemperle. Local Principal 
Investigator: Peter Ammann 
 
Hôpital Cantonal Fribourg: Mathieu Firmann, Sandrine Foucras. Local Principal Investigator: Daniel 
Hayoz 
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Ente Ospedaliero Cantonale Lugano:  Jane Frangi-Kultalahti, Anica Pin, Luisa Vicari Local Principal 
Investigator: Giorgio Moschovitis 
 
University Hospital Geneva: Georg Ehret, Hervé Gallet, Elise Guillermet, Francois Lazeyras, Karl-Olof 
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Data S1. 
 
Supplemental Methods  
 
Definition of study endpoints 
 
Mortality 
Deaths are categorized as either non-cardiovascular or cardiovascular. All deaths are assumed to be 
cardiovascular unless a non-cardiovascular cause can be clearly provided. 
Cardiovascular death includes a broad spectrum of cardiac deaths, such as cardiogenic shock, 
arrhythmia/sudden death, cardiac rupture, stroke, pulmonary embolism, ruptured aortic aneurysm or 
dissection. Furthermore, all hemorrhagic deaths are classified as cardiovascular deaths. 
Non-cardiovascular death requires a clear documentation of non-cardiac and nonvascular cause, for 
example respiratory failure (excluding cardiogenic pulmonary edema), neoplasm, infections/sepsis, 
and trauma (including suicide and homicide). 
 
Myocardial infarction 
A rise and/or fall of cardiac troponin with at least one value above the 99th percentile of the upper 
reference limit in a clinical setting consistent with myocardial infarction is required for the definition of 
myocardial infarction. Additionally, one of the following features is necessary: typical symptoms of 
ischaemia, new significant ST-T elevations and/or depressions, as well as left bundle-branch block on 
surface ECG, development of pathological Q waves on the ECG, imaging evidence of new regional 
wall motion abnormality or new loss of viable myocardium, identification of an intracoronary thrombus 
verified by angiography or autopsy.  
 
Stroke 
An acute focal neurological deficit of vascular origin consistent with imaging (computed tomography or 
cMRI) or autopsy is required for the definition of stroke. Stroke is classified as ischaemic, 
haemorrhagic or of unknown cause (based on imaging findings, or autopsy).TOAST classification is 
used for further differentiation of ischaemic stroke. Fatal stroke is defined as all-cause mortality within 
a timeframe of 30 days after stroke.  
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Bleeding 
Bleedings are divided into two different categories: 
 
1) We define major bleeding according to the criteria of the International Society on Thrombosis 
and Haemostasis, as overt bleedings with a fatal outcome, transfusion of at least two blood 
units, a drop in haemoglobin level of  ≥20 g/l within 7 days, or symptomatic bleeding in a 
critical organ (intracranial, intraspinal, intraocular, intra-articular, pericardial, retroperitoneal, 
intramuscular with compartment syndromvereine). 
2) Clinically relevant non-major bleeding is defined as a bleeding event that is clinically overt, 
and does not fulfill the criteria of a major bleeding event. These bleedings include:  
- hospital admission for bleeding or 
- a change in antithrombotic therapy or 
- physician guided medical or surgical treatment for bleeding.  
 
Hospitalization for congestive heart failure 
Hospitalization for acute heart failure is defined as: any hospitalization for acute heart failure that leads 
to at least one overnight stay. If it’s not clear whether the reason for a patient’s hospitalization is acute 
heart failure or not, this event/incidence should in doubt be classified as acute heart failure. The 
following clinical features could be used as an indication for heart failure: positive hepato-jugular 
reflux, rales and 3rd heart sound, leg swelling/leg edema and distension of the neck veins. 
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Table S1. Correlation between heart rate variability measures and clinical features.  
 HRVI SDNN RMSSD MHR 
HRVI  -0.021 0.287† -0.570† 
SDNN -0.021  0.566† 0.040 
RMSSD 0.287† 0.566†  0.033 
MHR -0.570† 0.040 0.033  
Age -0.066* 0.105† 0.173† 0.151† 
Duration of AF -0.035 -0.055* -0.125† -0.014 
CHA2DS2-VASc score -0.070† 0.067† 0.140† 0.142† 
Systolic blood pressure 0.093† -0.028 -0.010 -0.133† 
Diastolic blood pressure 0.066† -0.052* 0.032 -0.037 
Body mass index 0.250 0.009 0.420 0.103† 
AF symptoms# -0.061* -0.016 -0.038* 0.086† 
Sex  
Male 
 
14.7 (12.2-18.1) 
 
96.8 (66.5-140.0) 
 
42.7 (30.4-58.5) 
 
108.1 (71.3-148.6) 
Female 14.8 (12.3-18.5) 93.9 (59.1-143.8) 40.3 (29.1-55.2) 105.7 (73.1-147.5) 
Data represent Spearman`s rank correlation coefficient or median and interquartile ranges.  #According to EHRA classification. AF = atrial fibrillation.  HRVI = heart rate variability triangular index. MHR = mean heart rate. RMSSD = 
square root of the mean squared differences of successive normal-to-normal intervals. SDNN = standard deviation of the normal-to-normal intervals. *p<0.05, † p<0.005  
 
 
 
D
ow
nloaded from
 http://ahajournals.org by on A
ugust 10, 2020
Figure S1. Prognostic impact of heart rate variability triangular index assessed during atrial fibrillation. Kaplan-Meier curves of cardiovascular 
mortality stratified by the median heart rate variability triangular index. 
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Figure S2. Prognostic impact of heart rate variability triangular index assessed during sinus rhythm. Kaplan-Meier curves of cardiovascular mortality 
stratified by the median heart rate variability triangular index. 
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